期刊文献+

凝血因子Ⅷ/Ⅸ抑制物诊断与治疗中国指南(2018年版) 被引量:49

Chinese guidelines on the diagnosis and treatmentof coagulation factor VIII/IX inhibitors (version2018)
原文传递
导出
摘要 近年来,无论是获得性凝血因子Ⅷ(FⅧ)/凝血因子Ⅸ(FⅨ)抑制物(也称获得性血友病)还是血友病患者合并抑制物均有增多的趋势。前者是非血友病患者产生的抗FⅧ/FⅨ自身抗体,后者是血友病患者接受外源性凝血因子产品输注后产生的抗FⅧ/FⅨ同种抗体。重型血友病A患者抑制物发生率约为30%,非重型为3%-13%,而血友病B患者为1%-6%[1]。为了规范国内同行的诊疗行为并为有关部门制定政策提供依据,我们曾先后制订了相关中国专家共识。为进一步提高我们对FⅧ/FⅨ抑制物的认识,做到发现及时、处理正确,特制订此指南供国内同行参考。
作者 杨仁池 中华医学会血液学分会血栓与止血学组 中国血友病协作组 Thrombosis and Hemostasis Group, ChineseSociety of Hematology, Chinese Medical Association, Hemophilia Treatment Center Collaborative Network of China,Yang Renchi(State Key Laboratory of Experimental Hematology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300020, China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2018年第10期793-799,共7页 Chinese Journal of Hematology
基金 “十三五”国家重点研发计划精准医学研究重点专项(2016YFC0901503) 中国医学科学院医学与健康科技创新工程重大协同创新项目(2016-12M-1-002)
  • 相关文献

参考文献4

二级参考文献18

  • 1Rocino A,Santagostino E,Mancuso ME,et al.Immune tolerance induction with recombinant factor Ⅷ in hemophilia A patients with high responding inhibitors.Haematologica,2006,91:558-561.
  • 2Gouw SC,van den Berg HM.The multifactorial etiology of inhibitor development in hemophilia:genetics and environment.Semin Thromb Hemost,2009,35:723-734.
  • 3Wang XF,Zhao YQ,Yang RC,et al.The prevalence of factor Ⅷ inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A.Haemophilia,2010,16:632-639.
  • 4Dasgupta S,Repessé Y,Bayry J,et al.vWF protects FⅧ from endocytosis by dendritic cells and subsequent presentation to immune effectors.Blood,2007,109:610-612.
  • 5Lacroix-Desmazes S,Navarrete AM,André S,et al.Dynamics of factor Ⅷ interactions determine its immunologic fate in hemophilia A.Blood,2008,112:240-249.
  • 6Ghosh K,Shetty S.Immune response to FⅧ in hemophilia A:an overview of risk factors.Clin Rev Allergy Immunol,2009,37:58-66.
  • 7Goudemand J,Rothschild C,Demiguel V,et al.Influence of the type of factor Ⅷ concentrate on the incidence of factor Ⅷ inhibitors in previously untreated patients with severe hemophilia A.Blood,2006,107:46-51.
  • 8Tellier Z,André MH,Polack B.Management of haemophilia Ainhibitor patients:clinical and regulatory perspectives.Clin Rev Allergy Immunol,2009,37:125-134.
  • 9Franchini M.Recombinant factor Ⅶa:a review on its clinical use.Int J Hematol,2006,83:126-138.
  • 10Abshire T,Kenet G.Safety update on the use of recombinant factor Ⅶa and the treatment of congenital and acquired deficiency of factor Ⅷ or Ⅸ with inhibitors.Haemophilia,2008,14:898-902.

共引文献239

同被引文献306

引证文献49

二级引证文献233

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部